Hummingbird Bioscience Announces US FDA Clearance Of IND For First-in-Human Phase 1 Trial Of HMBD-002 In Patients With Advanced Solid Tumors

HOUSTON and SINGAPORE, Sept. 13, 2021 /PRNewswire/ — Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the U.S. Food and Drug Administration (FDA) has approved the initiation of a Phase …
Read More